Latest From Advantagene Inc.
Arteaus sells royalty stream from Lilly's Emgality giving investors a $260m payday. Also, Pfizer spin-out SpringWorks nabs another $125m, Arch Oncology and Prevail Therapeutics close $50m Series B rounds, and Karuna's recent financing grows to $80m.
The Phase III PROSPECT study's data monitoring committee decides against continuing after interim analysis. The fall-out could hit Bavarian Nordic’s CV301 too.
Janssen reported treatment altering Phase III data at ASCO 2017 for a new Zytiga combination targeting hormone-naïve metastatic prostate cancer patients – but the triple regimen's relevance might be short-lived as momentum builds in the late-stage pipeline.
The sector still attracts the attention of clinical investigators and the pharmaceutical industry, despite disappointing results from another clinical-stage candidate.
- Gene Therapy, Cell Therapy
- Large Molecule
- Drug Delivery
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Advantagene Inc.
- Senior Management
Estuardo Aguilar-Cordova, MD, PhD, CEO
Laura Aguilar, MD, PhD, CMO
Stephen Rocamboli, CBO
Brian Guzik, PhD, Sr. Dir., Bus. Dev.
- Contact Info
Phone: (617) 916-5445
440 Lexington St.
Auburndale, MA 02466
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.